Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 61 to 70 of 118 total matches.
Futibatinib (Lytgobi) for Cholangiocarcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
studies.
Women of reproductive potential and their male
partners should use effective contraception ...
The oral kinase inhibitor futibatinib (Lytgobi –
Taiho) has received accelerated approval from the
FDA for treatment of adults with previously treated,
unresectable, locally advanced or metastatic
intrahepatic cholangiocarcinoma with fibroblast
growth factor receptor 2 (FGFR2) fusions or other
rearrangements. Accelerated approval was based
on the overall response rate and duration of
response. Futibatinib is the second drug to be
approved for this indication; pemigatinib (Pemazyre)
was approved earlier.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e69-70 doi:10.58347/tml.2023.1674f | Show Introduction Hide Introduction
Polatuzumab vedotin (Polivy) for Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
with female partners of reproductive potential
should use effective contraception during treatment
DLBCL ...
Polatuzumab vedotin-piiq (Polivy – Genentech), a
CD79b-directed antibody and microtubule inhibitor
conjugate, has been approved by the FDA for use
in combination with rituximab, cyclophosphamide,
doxorubicin, and prednisone (R-CHP) for first-line
treatment of diffuse large B-cell lymphoma
(DLBCL), not otherwise specified (NOS), or high-grade
B-cell lymphoma (HGBL) in adults who have
an International Prognostic Index (IPI) score ≥2. The
drug was previously approved for use in combination
with bendamustine and rituximab for treatment of
patients with relapsed or refactory DLBCL,...
Med Lett Drugs Ther. 2023 May 29;65(1677):e89-90 doi:10.58347/tml.2023.1677f | Show Introduction Hide Introduction
Asciminib (Scemblix) for Chronic Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
effective contraception during
treatment with asciminib and for one week after
the last dose ...
Asciminib (Scemblix – Novartis), an oral kinase
inhibitor, has been approved by the FDA for treatment
of adults with Philadelphia chromosome-positive
chronic myeloid leukemia (Ph+ CML) in chronic
phase (CP) previously treated with ≥2 tyrosine kinase
inhibitors and for adults with Ph+ CML in CP with a
T315I mutation.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e107-8 doi:10.58347/tml.2023.1678g | Show Introduction Hide Introduction
Elranatamab (Elrexfio) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
effective
contraception during treatment with elranatamab
and for 4 months after the last dose ...
Elranatamab-bcmm (Elrexfio – Pfizer), a bispecific
B-cell maturation antigen (BCMA)-directed CD3
T-cell engager, has been granted accelerated
approval by the FDA for treatment of relapsed or
refractory multiple myeloma in adults who received
≥4 prior lines of therapy, including a proteasome
inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Accelerated approval
was based on the response rate and durability of
response. Elranatamab is the second bispecific
BCMA-directed CD3 T-cell engager to be approved for
this indication; teclistamab (Tecvayli) was the...
Med Lett Drugs Ther. 2023 Sep 18;65(1685):e153-4 doi:10.58347/tml.2023.1685d | Show Introduction Hide Introduction
Tepotinib (Tepmetko) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
was teratogenic. Females with
reproductive potential and their male partners
should use effective contraception ...
The FDA has granted regular approval to the oral
kinase inhibitor tepotinib (Tepmetko – EMD Serono)
for treatment of adults with metastatic non-small
cell lung cancer (NSCLC) harboring mesenchymal-epithelial
transition (MET) exon 14 skipping
alterations. MET exon 14 skipping mutations occur
in 3-4% of NSCLC cases and are associated with
advanced disease and a poor prognosis. Tepotinib
received accelerated approval for the same indication
in 2021 based on initial overall response rates and
duration of response.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):e73-4 doi:10.58347/tml.2024.1701f | Show Introduction Hide Introduction
Pemigatinib (Pemazyre) for Cholangiocarcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
partners should use effective contraception
during treatment with pemigatinib and for 1 week after ...
The oral kinase inhibitor pemigatinib (Pemazyre –
Incyte) has received accelerated approval from
the FDA for treatment of adults with previously
treated, unresectable, locally advanced or metastatic
cholangiocarcinoma with fibroblast growth factor
receptor 2 (FGFR2) fusions or other rearrangements.
Pemigatinib is the first drug to be approved in the US
for this indication.
Teprotumumab (Tepezza) for Thyroid Eye Disease
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
.
Women of childbearing potential should use effective
contraception before starting treatment, during ...
Teprotumumab-trbw (Tepezza - Horizon), an insulin-like
growth factor-1 receptor (IGF-1R) inhibitor, has
been approved by the FDA for IV treatment of thyroid
eye disease. It is the first drug to be approved in the US
for this indication.
Amivantamab (Rybrevant) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
use effective contraception during
treatment with amivantamab and for 3 months after
the last dose ...
Amivantamab-vmjw (Rybrevant – Janssen), an EGFR-MET
bispecific antibody, has received accelerated
approval from the FDA for IV treatment of locally
advanced or metastatic non-small cell lung cancer
(NSCLC) with epidermal growth factor receptor
(EGFR) exon 20 insertion mutations in adults whose
disease has progressed on or after platinum-based
chemotherapy. It is the first bispecific antibody
to become available in the US for this indication.
Accelerated approval of the drug was based on the
overall response rate and duration of response.
Teclistamab-cqyv (Tecvayli) For Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
of
childbearing potential should use effective contraception
during treatment with teclistamab and for
5 months ...
Teclistamab-cqyv (Tecvayli – Janssen), a bispecific
B-cell maturation antigen (BCMA)-directed CD3
T-cell engager, has been granted accelerated
approval by the FDA for treatment of relapsed or
refractory multiple myeloma in adults who received
≥4 prior lines of therapy, including a proteasome
inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Accelerated approval
was based on response rate. Teclistamab is the first
bispecific BCMA-directed CD3 T-cell engager to be
approved in the US.
Glofitamab (Columvi) for Diffuse Large B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
should use effective
contraception during treatment with glofitamab and
for 1 month after the last dose ...
Glofitamab-gxbm (Columvi – Genentech), a bispecific
CD20-directed CD3 T-cell engager, has received
accelerated approval from the FDA for IV treatment of
relapsed or refractory diffuse large B-cell lymphoma
(DLBCL), not otherwise specified, or large B-cell
lymphoma (LBCL) arising from follicular lymphoma
after ≥2 lines of systemic therapy. Accelerated
approval was based on response rates and durability
of response. Glofitamab is the second T-cell-engaging
bispecific antibody to be approved in the US
for treatment of DLBCL; epcoritamab-bysp (Epkinly),
which is given...
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e129-30 doi:10.58347/tml.2023.1682b | Show Introduction Hide Introduction